Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > New Corporate Presentation is up

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Mar 05, 2021 9:22pm

165 Views

Post# 32735047

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New Corporate Presentation is up

That works for me - let's hope the FDA sees it the same way.

SPCEO1 wrote:
palinc2000 wrote: You mean 18 mos after full enrolment?
I mean 18 mos or so after start ot the trial when DSMB looks at interim redults for safety and efficacy
SPCEO1 wrote: They are going for full approval after 18 months of data - right? I will take the HIV NASH label as soon as they are willing to give it. The sooner the better from the patient's perspective.

palinc2000 wrote: How about a label expansion for Nash Hiv patients 18 mos into the trial after an interim review by DSMB ,,,,,

palinc2000 wrote: I have learned from SPCEO to read between the lines,So in reading between the lines I think they want the reader to conclude that the 75-100 Hiv patients cohort in the Nash trial has a good chance of success and that alone would represent a major market opportunity,,,,

I really enjoy reading their confidence level in getting substantial growth in sales of existing product